Skip to main content
. 2023 Oct 16;18:326. doi: 10.1186/s13023-023-02925-w

Fig. 5.

Fig. 5

Scatterplot of probabilistic sensitivity analysis for all randomized patients. A All randomized patients, NI Nivolumab plus ipilimumab, C Pemetrexed plus cisplatin/carboplatin, WTP Willingness to pay, QALY Quality-adjusted life year